Member Info for BTFATH1

£1 would be great for starters

Today someone is also putting in continuous buys of under 5k :-)

Always good to be cynical but why post when you are not invested??? Agenda that is why

3x versus sells :-)))

Yep should see £1.20-£1.30 this week. I will take half off the table when it gets there and hold medium term in the rest

Either short or wants a lower entry absolute fine to deramp but you have to acknowledge this is very undervalued at present. Net assets are over £400 million and they are fully funded. Great summary bud btw attack on a quid happening again. £1.09 close is my bet

Just wait and be patient this is being held back still.

Well I stated buying at 96p then 92p then 87p so how can that be the case? At sub £1 this is a huge bargain

Ha ha got to be done when it undervalued doing it in amongst a busy day job - not easy :-))

Well if we had listened to you yesterday trying to convince everyone to sell :-)))

Chuck in sells of less than 100 shares and it reduced the sp disguising the big buys that are going through

Continuing just let it go corrupt ones please

Would expect to see a confirmation of Woodford increasing soon

They are playing around with this today

Buy drop way way overdone as we all knew: paleje: Tempus in today's Times says its a buy. http://www.thetimes.co.uk/edition/business/dividend-safe-with-grid-lights-staying-on-whw22qwzb When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever. This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever. Any biotech company is always going to be speculative, but this looks a good gamble. MY ADVICE Buy WHY Risky, but the share price fall looks overdone

£1.02 now mate :-)))

Gone :-)))))) £1.20 next

£1 about to go got to remember they also have a large revenue stream this is not a 1 trick pony like the sp reacted yesterday.

Will start buying big here to average down

20,000 plus buys coming in